When CVS Well being lastly revealed how it could present follow-on variations of the blockbuster immunology drug Humira, it selected a unique path than its friends. Moderately than deciding on a number of biosimilars so as to add to its listing of coated medication as different pharmacy profit managers did, CVS solely introduced one, and that model of the drug would come by way of a brand new firm known as Cordavis.
CVS mentioned in its late August announcement that establishing a subsidiary to supply biosimilars will decrease the price of most of these medication whereas guaranteeing availability of the merchandise. However business observers say there’s extra to the technique. This construction will make the corporate more cash, in response to Nathan Ray, a companion at healthcare and life sciences consultancy West Monroe. CVS has seemingly run fashions evaluating what the corporate would make by providing a number of Humira biosimilars versus having a hand in an organization that commercializes it. Profitability is the one cause for the corporate to arrange Cordavis to supply the drug, he mentioned.
Woonsocket, Rhode Island-based CVS didn’t reply to a message looking for remark. In its announcement, the corporate mentioned Cordavis, a newly launched subsidiary, will work instantly with producers to commercialize or co-produce biosimilars. CVS added it intends to develop a portfolio of biosimilars, however the one one disclosed to date is Hyrimoz, the Humira biosimilar from Sandoz.
CVS mentioned Cordavis has contracted with Sandoz to commercialize Hyrimoz beneath a Cordavis personal label. Cordavis expects a primary quarter 2024 launch of this biosimilar, which it mentioned can be priced greater than 80% decrease than branded Humira. Humira, made by AbbVie, prices $6,992 a month, in response to the Drug Analysis Institute, a drug business analysis group. Sandoz has priced Hyrimoz at $6,576, a 5% low cost to Humira.
Different PBMs are becoming a member of the biosimilar market in a extra conventional means, providing follow-on variations to the AbbVie biologic drug alongside that branded product. Optum Rx’s Humira biosimilar choices embrace Hyrimoz, the Boehringer Ingelheim product Cyltezo, and Amgen’s Amjevita. Categorical Scripts is providing Cyltezo and two Sandoz merchandise: Hyrimoz and an unbranded model of that drug.
Cordavis shouldn’t be first new entity created by CVS to deliver lower-priced variations of pharmaceuticals to the market. In 2013, the corporate introduced the formation of Purple Oak, a 50/50 three way partnership with Cardinal Well being. Purple Oak sources and negotiates drug provide contracts for each Cardinal Well being and CVS. Purple Oak solely handles generic medication, usually tablets. Now Cordavis will play an identical position for CVS in biosimilars.
Based on Drug Channels Institute CEO Adam Fein, Cordavis will allow CVS to enhance its profitability in a number of methods. For instance, CVS might take in a portion of a biosimilar producer’s revenue margin, Fein wrote in an article posted on the Drug Channels web site. Different examples embrace establishing proprietary acquisition value benchmarks that allow it to achieve increased reimbursement from plan sponsors. Cordavis additionally locks in for CVS a most popular provide supply for its Humira biosimilar.
Whereas CVS mentioned Hyrimoz is the primary of a number of biosimilar merchandise that Cordavis will supply, it didn’t say whether or not the brand new entity will supply different Humira biosimilars. Ray mentioned that whereas there could also be an incentive for folks to take Hyrimoz versus one other product, it’s unclear how CVS or Cordavis will assist sufferers decide what’s proper for them. He added that solely sure medication could also be worthwhile sufficient to pursue beneath the Cordavis mannequin. But when this mannequin proves to be extra worthwhile for CVS, he expects different PBMs might observe.
“I’m imagining that as it’s, this shall be a check mattress,” Ray mentioned. “We’ll see the way it works out. Simply saying they’re going to do one thing and really doing it may be far aside in timeline and never at all times work out as anticipated.”
Photograph: Justin Sullivan/Getty Photographs